Phase 3Active, not recruiting
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity (TRIUMPH-5)
A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Retatrutide Compared to Tirzepatide in Adults Who Have Obesity
- Sponsor
- Eli Lilly and Company (Industry)
- Enrollment
- 800 planned
- Conditions
- Obesity
- Interventions
- Retatrutide; Tirzepatide
- Ages
- adults, older adults
- Registry
- NCT06662383, CTIS2024-511450-49-00
Full record on ClinicalTrials.gov
From the registry
The main purpose of this study is to evaluate the efficacy and safety of retatrutide compared to tirzepatide in adults who have obesity. The study will last about 89 weeks.
Primary outcomes
- Percent Change from Baseline in Body Weight
History
Study completion expected
Primary completion expected
Last registry update
Started
Registered
In the news
TrialsNature Medicine (opens Nature Medicine in a new tab)
Resistance training cuts lean mass loss by 1.09 kg during tirzepatide obesity therapy
In a 40-week randomized trial involving 120 adults, three weekly sessions improved strength while weight loss matched tirzepatide alone, researchers report.
TrialsMedical Xpress (opens Medical Xpress in a new tab)
Lilly’s retatrutide at least halves knee osteoarthritis pain in two-thirds of participants
Two Northwestern-led phase 3 trials enrolled over 1,000 adults with overweight or obesity; 38% on placebo achieved comparable pain relief, while the highest dose produced roughly 25% weight loss.
Also in NEJM (opens NEJM in a new tab), Yonhap News Agency (opens Yonhap News Agency in a new tab)
CompanyGlobeNewswire (opens GlobeNewswire in a new tab)
Eli Lilly's retatrutide leads recall across the obesity drug pipeline
The candidate leads recall among obesity treatments in development.
TrialsSTAT+ (opens STAT in a new tab, subscription)
Eli Lilly says retatrutide lowers blood sugar and weight more than Ozempic in diabetes
The large head-to-head study tested Lilly’s investigational incretin injection against Novo Nordisk’s drug.
Also in Endpoints News (opens Endpoints News in a new tab), BioPharma Dive (opens BioPharma Dive in a new tab), ByDrug (opens ByDrug in a new tab), Diario Médico (opens Diario Médico in a new tab), asiae.co.kr (opens asiae.co.kr in a new tab), oe24 (opens oe24 in a new tab)